Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and ipilimumab in untreated unresectable stage III non-small cell lung cancer
NL-OMON59644Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival. Started Oct 2020; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59644.